ReviewFrontiers in immunology2026
Transposable elements as a possible missing link between genetic predisposition and environmental triggers of autoimmune disorders: insights from type 1 diabetes, systemic lupus erythematosus and rheumatoid arthritis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transposable elements (TEs) make up almost half of the human genome and are among its most densely methylated regions. Their epigenetic silencing is crucial for genomic stability and immune homeostasis, and accumulating evidence indicates that dysregulated TE methylation and expression contribute to autoimmune disease pathogenesis. Hypomethylation of selected TE families can permit transcriptional reactivation, production of immunostimulatory nucleic acids and peptides, and engagement of pattern-recognition receptors, thereby driving type I interferon (IFN-I) signaling through "viral mimicry"-like mechanisms. In parallel, TE-derived enhancers, promoters and exons reshape gene regulatory networks at immune loci. In this narrative review, we synthesize current knowledge on TE methylation and expression in autoimmunity, with a focus on type 1 diabetes (T1D), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We first outline TE biology and the principal mechanisms of epigenetic silencing, then summarise methodological advances for TE methylation and expression profiling, including long-read sequencing and TE-aware RNA-seq pipelines. We next dissect disease-specific evidence: longitudinal epigenomic studies in T1D showing preclinical DNA methylation changes and altered Alu/LINE-1 patterns, together with HERV-H/W upregulation at onset, SLE studies demonstrating LINE-1 hypomethylation in neutrophils and cell-type-specific TE overexpression that tracks with IFN signatures and nucleic acid sensor pathways, and RA studies linking global and LINE-1 methylation to methotrexate response when integrated with serostatus. Across conditions, TE methylation behaves more like a relatively stable disease-associated trait than a simple activity marker and exhibits clear disease- and cell-type-specific signatures rather than global hypomethylation. We conclude that TEs are not passive genomic relics but epigenetically regulated elements that can act as endogenous sources of immunostimulatory nucleic acids, neoantigens and regulatory sequences, providing a mechanistic bridge between genetic susceptibility and environmental triggers in autoimmunity. Consequently, selective dysregulation of TE methylation and expression offers both an explanatory framework for interferon-driven autoimmunity and a promising, currently underused layer for biomarker development and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.